Buy & Sell Royal Bank of Canada (RY) – Royal Bank of Canada Price Today
Key Stats
- $275.04BMarket Cap
- FinancialsSector
- -4.33%3M Drawdown
- -Enterprise Value
- 2.58%Dividend Yield
- 98% Buy | 2% SellTrading Activity
- 43 daysTypical Hold Time
Royal Bank of Canada (RY) is currently valued at a market capitalization of $275.04B. Over the past 52 weeks, Royal Bank of Canada has traded between a low of $127.19 and a high of $198.16, highlighting its annual price range. Over the past three months, Royal Bank of Canada has recorded a drawdown of -4.33%, reflecting recent price volatility. Royal Bank of Canada offers a dividend yield of 2.58%, with the most recent dividend of $1.64 paid on 23 Apr 26. On average, investors hold Royal Bank of Canada for approximately 43 days, indicating typical investor behavior on the platform.
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Most Recent News
ConocoPhillips director sells shares amid oil price drop and rising supply concerns
A director at ConocoPhillips sold 1,974 shares worth about $235,000 following a 2.2% drop in the company's stock price amid a broader oil market downturn. The decline in oil prices was driven by increasing global supply, with key indicators like Bren...
Global Initiative on Loneliness and Connection hosts forum to tackle social division and loneliness worldwide
The Global Initiative on Loneliness and Connection (GILC) convened the 2026 Global Connection Forum on June 17 to address the growing public health crisis of loneliness and social isolation, which contribute to serious health risks and societal divis...
Metastatic prostate cancer market to grow strongly through 2036 with new targeted therapies emerging.
The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...
